Exjade Tablet, For Suspension
Product Images NDC 0078-0470

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Exjade (NDC 0078-0470). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Deferasirox Structural Formula. (Exjade 01)

Chemical structure diagram of deferasirox, the active ingredient in Exjade, showing its molecular composition and arrangement.*

FDA Label Image

Figure 1. Changes In Liver Iron Concentration And Serum Ferritin Following Exjade (5 30 mg/kg Per Day) In Study 1. (Exjade 02)

Bar chart illustrating the changes in liver iron content and serum ferritin levels at various doses of Exjade (deferasirox) in mg/kg/day. The x-axis shows dose groups (5, 10, 20, and 30 mg/kg/day) with sample sizes. Two bars per group represent mean changes in liver iron content (mg Fe/g dw) and serum ferritin (mcg/L) with standard error bars.*

FDA Label Image

Principal Display Panel – Package Label – 125 mg Tablets (Exjade 03)

Exjade 125 mg tablets for oral suspension by Novartis Pharmaceuticals Corporation. The label displays the product's proprietary and generic name, dosage strength, and instructions for pharmacists to dispense with accompanying medication guides. The package contains 30 tablets, and specific directions indicate the tablets must be dispersed in water or juice before ingestion. Additional prescribing and storage information is also included on the label.*

FDA Label Image

Principal Display Panel – Package Label – 250 mg Tablets (Exjade 04)

Exjade 250 mg tablets for oral suspension by Novartis Pharmaceuticals Corporation. The label identifies the product as deferasirox in tablet form for suspension, with instructions to disperse tablets in water, orange, or apple juice before ingestion. The package contains 30 tablets and is marked Rx only.*

FDA Label Image

Principal Display Panel – Package Label – 500 mg Tablets (Exjade 05)

Exjade 500 mg tablets for oral suspension label with NDC 0078-0470-15. The label indicates the product contains deferasirox as the active ingredient and is for prescription use only. It includes dispensing instructions to dissolve tablets in water, orange, or apple juice before ingestion. The label shows a package size of 30 tablets and is labeled by Novartis Pharmaceuticals Corporation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.